The 5 most recent market catalysts affecting $LPCN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 5, 2026
Corporate Catalyst
Bearish
Impact 80
Lipocine Inc. Reports Third Quarter 2026 Financial Results
Lipocine Inc. announced a net loss of $0.7 million for Q3 2026, a significant improvement from the $3.2 million loss in Q3 2025. This narrowing loss is primarily due to a substanti…
Oct 7, 2026
Corporate Catalyst
Bullish
Impact 75
Canadian Approval Of Lipocine Drug Marks Progress for Oral Testosterone Options In Canada
Health Canada's approval of TLANDO is a significant positive development for Lipocine Inc. and its partner Verity Pharmaceuticals. This expands TLANDO's market reach beyond the U.S…
Oct 7, 2026
Corporate Catalyst
Bullish
Impact 85
Lipocine shares are trading higher after the company announced that Health Canada approved TLANDO for testosterone replacement therapy in adult males.
The Health Canada approval of TLANDO for Lipocine is a major corporate catalyst, directly impacting the company's revenue potential and market valuation. This regulatory milestone …
Sep 21, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Neutral on Lipocine, Announces $4 Price Target
HC Wainwright & Co. analyst Yi Chen reiterated a Neutral rating on Lipocine (LPCN) and announced a $4 price target. This action is significant as it provides an updated professiona…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 65
Lipocine Q2 EPS $(0.32) Beats $(0.43) Estimate, Sales $190.099K Beat $156.500K Estimate
Lipocine's Q2 earnings report presents a mixed picture. While the company successfully beat analyst estimates for both EPS and sales, the substantial year-over-year decline in sale…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.